-
Innovation Ranking
NewInnovation Ranking – I-Mab
I-Mab(I-Mab) is a biopharmaceutical company. It develops transformational medicines for therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with...
-
Innovation Ranking
NewInnovation Ranking – Data I/O Corp
Data I/O Corp (Data I/O) is a provider of manual and automated security provisioning and device programming systems for Flash, Microcontroller and Logic devices. The company provides programming solutions such as products, systems, modules and accessories, grouped into two categories. Data I/O offers solutions such as automated programming systems and manual programming systems, among others. The company serves industries such as automotive electronics, industrial controls, wireless devices, programming centers, medical devices, among others. Data I/O provides two categories of automated...
-
Innovation Ranking
NewInnovation Ranking – O-I Glass Inc
O-I Glass Inc (O-I Glass) is a global manufacturer of glass containers. Its product portfolio includes a wide range of glass bottles and jars in various sizes, shapes and colors. The company’s containers find application in packaging of alcoholic beverages, ready-to-drink low alcohol refreshers, food, wine, spirits, soft drinks, and other non-alcoholic beverage products and also for pharmaceuticals and chemical products. Key customers of the company include Anheuser-Busch InBev, Heineken, Molson Coors, Brown-Forman, Carlsberg, Constellation, Coca-Cola, Diageo, PepsiCo, Pernod Ricard...
-
Product Insights
NewLikelihood of Approval Analysis for Type I Hypersensitivity
Overview How likely is it that the drugs in Type I Hypersensitivity will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Type I Hypersensitivity Overview Type 1 hypersensitivity is a type of...
-
Product Insights
NewLikelihood of Approval Analysis for Bipolar I Disorder
Overview How likely is it that the drugs in Bipolar I Disorder will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bipolar I Disorder Overview Bipolar I Disorder is a mental health...
-
Innovation Ranking
NewInnovation Ranking – Seven & i Holdings Co Ltd
Seven & i Holdings Co Ltd (Seven & i Holdings) is a diversified retailing company that manages and operates various businesses through its subsidiaries and franchises. It operates convenience stores, supermarkets, departmental stores, specialty stores, e-commerce platforms, and restaurants. These stores offer food, processed food, frozen food, gasoline, non-food items, apparel, and household goods. Seven & i Holdings also provides Internet-related services, meal delivery services, and various banking and financial services such as ATM, electronic money, credit cards, insurance, and...
-
Product Insights
NewLikelihood of Approval Analysis for Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Overview How likely is it that the drugs in Neurofibromatoses Type I (Von Recklinghausen's Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neurofibromatoses Type I (Von Recklinghausen's Disease) Overview Neurofibromatosis...
-
Product Insights
NewNet Present Value Model: Cellectar Biosciences Inc’s Iopofosine i-131
Empower your strategies with our Net Present Value Model: Cellectar Biosciences Inc's Iopofosine i-131 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JWK-008 in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JWK-008 in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JWK-008 in Mucopolysaccharidosis I (MPS I) (Hurler...